Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$6.02 USD
+0.01 (0.17%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.00 -0.02 (-0.33%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
COGT 6.02 +0.01(0.17%)
Will COGT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for COGT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COGT
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why
COGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
Other News for COGT
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Cogent Biosciences presents preclinical data of CNS-penetrant ErbB2 inhibitor
Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options
Cogent Biosciences files to sell 31.2M shares of common stock for holders